43 results about "Amyloid A Protein" patented technology

Peptides and mimetics of selected domains of mammalian serum amyloid A isoform 2.1 (SAA2.1) and compounds and compositions thereof are provided that enhance the effect on macrophage cholesterol ester hydrolase activity and/or inhibit acyl CoA:cholesterol acyl transferase activity. Methods of using these compositions in the treatment and/or prevention of atherosclerosis as well as coronary heart disease and cardiovascular disease are also provided.

The invention discloses a kit for detecting the content of a serum amyloid protein A. The kit comprises a reagent R1, a reagent R2 and a serum amyloid protein A calibrator, wherein the reagent R1 comprises a first buffer solution, a first electrolyte, a surfactant, a first stabilizer, a high-molecular accelerant and a first preservative; the reagent R2 comprises a second buffer solution, anti-human serum amyloid protein A antibody coated latex particles, a second electrolyte, a second stabilizer and a second preservative; the serum amyloid protein A calibrator comprises a third buffer solution, a third stabilizer, a third preservative, an antioxidant and an anti-human serum amyloid protein A antigen. The invention further discloses an application of the kit for detecting the content of the serum amyloid protein A to the detection of the content of the serum amyloid protein A and a method for detecting the content of the serum amyloid protein A by adopting the kit for detecting the content of the serum amyloid protein A. By adopting the kit and the method disclosed by the invention, the content of the serum amyloid protein A can be detected easily and rapidly.

The invention discloses a detection kit for human serum amyloid A protein. The detection kit is characterized by comprising a reagent R1 and a reagent R2, the reagent R1 is an appropriate buffer solution, and the reagent R2 is prepared by putting polystyrene latex particles sensitized by a human serum amyloid A protein antibody into the appropriate buffer solution. The detection kit has the advantages of being simple and fast in detection, high in sensitivity, good in accuracy, high in anti-jamming capability and low in production cost.

The invention relates to a fluorescence immunochromatographic method of serum amyloid protein A and a detection kit thereof. The method includes the steps of preparing a probe fixing pad, preparing an immunochromatographic test strip, preparing a sample diluting liquid and detecting a sample. The probe fixing pad is prepared by mixing serum amyloid protein A monoclonal antibody fluorescent latex particles and goat-anti-rabbit IgG fluorescent latex particles, and diluting the mixture with a gold diluent and spraying the liquid onto glass fibers. A detection line is coated with serum amyloid protein A monoclonal antibody and a control line is coated with goat-anti-rabbit IgG to prepare the immune-chromatographic test strip. The detection kit includes an immune-chromatographic detection card including a PVC lining plate, a sample pad, the probe fixing pad, a nitrocellulose membrane and a water absorbing paper. The probe fixing pad is prepared by mixing and drying the serum amyloid protein A monoclonal antibody fluorescent latex particles and the goat-anti-rabbit IgG fluorescent latex particles, so that the detection kit is high in detection sensitivity and accuracy, is simple in operation and is low in cost.

The invention relates to a kit for quickly and quantificationally detecting serum amyloid A (SAA) by using an immunogold method. The kit includes lyophilized anti-SAA immunogold, a reaction plate, a sample diluent, a lyophilized colloidal gold complex solution, a scrubbing solution and a sealing solution. The preparation method comprises the following steps: (1) firstly preparing a conjugate of the colloidal gold and anti-SAA immunogold, and preparing lyophilized anti-SAA immunogold; and (2) preparing the sample diluent, the lyophilized colloidal gold complex solution, the scrubbing solution and the sealing solution according to the proportion, preparing the reaction plate, and assembling the prepared objects to a finished product to obtain the kit. By using the kit provided by the invention, a doctor can obtain an SAA measurement result on the spot when a person is ill so as to quickly judge the patient's condition, so that more targeted treatment can be effectively taken on the patient, healing time is shortened and medical cost is reduced. The kit provided by the invention has a good application prospect.

The invention belongs to the fields of biotechnologies and genetic engineering technologies and in particular relates to an efficient soluble expression and purification method of Abeta42 in escherichia coli. An Abeta42 expression system constructed by the invention provides a construction method of an expression vector of prokaryote for soluble fusion expression of human amyloid protein Abeta42 and the expression vector is introduced into an escherichia coli expression host; target Abeta42 with high-purity bioactivity is obtained through induced expression, protein enzyme digestion, two-step purification and identification. According to the method provided by the invention, an escherichia coli expression system and fusion protein have the characteristics of high expression efficiency, large expression amount, low cost, easiness for operation and the like; an expressed Abeta42 polypeptide has the advantages of no residues, high purity, high productivity and the like.

The embodiment of the invention relates to the field of immunodetection, in particular to a human serum amyloid protein A determination kit with high sensitivity and a wide detection range. The humanserum amyloid protein A determination kit comprises a reagent 1, a reagent 2 and SAA calibrators with different concentration gradients, wherein the reagent 2 comprises carboxylated latex microspheresonly labeled with human SAA monoclonal antibodies and carboxylated latex microspheres only labeled with human SAA polyclonal antibodies; the average particle size of the carboxylated latex microspheres only labeled with the human SAA monoclonal antibodies is larger than the average particle size of the carboxylated latex microspheres only labeled with the human SAA polyclonal antibodies. The kitcan be used for detecting a single sample within 10 minutes; the kit has the advantages that the kit is simple in structure and excellent in precision, accuracy, linearity, interference resistance andother indexes, can well diagnose early inflammation of infectious diseases, can detect the content of SAA in serum and the content of SAA in blood plasma, is very suitable for clinical biochemical analyzers, and greatly facilitates clinical examination.

The invention discloses an application of gastrodin to preparing medicaments for preventing and treating Alzheimer's disease. Alzheimer's disease (AD) is a neurodegenerative disease, and pathological characteristics comprise neuro fibrillary tangles formed in cells, hyperplasia of reactive microglia and glial cell, and the like, wherein the extracellular deposition of amyloid A beta is the main pathogenetic reason of AD. An AD small mouse taking a gastrodin-containing fodder is substantially improved in spatial-memory learning ability, substantially reduced in A beta level in brain and serum, and substantially reduced in amyloid plaques and microglia in brain tissue, and thus it is indicated that gastrodin is capable of preventing A beta deposition and decreasing active components causing AD mouse brain gastrodin.

The invention provides a kit for detecting serum amyloid A content and a preparation method and detection method thereof and belongs to the field of medical detection. The kit comprises a hemolytic agent R1 and a latex reagent R2 which are independent with each other. The latex reagent R2 comprises latex coated with a serum amyloid A antibody. The latex coated with the serum amyloid A antibody isprepared from latex having particle sizes of 60-130nm and coated with the anti-serum amyloid A1 antibody and latex having particle sizes of 190-220nm and coated with the anti-serum amyloid A2 antibodythrough mixing. The invention also provides a preparation method and a detection method of the kit for detecting serum amyloid A content. The kit can detect whole blood, serum, a cerebrospinal fluidand a pleuroperitoneal fluid, utilizes a small amount of samples, is free of separation or pretreatment, can be directly used for detection and has good sample compatibility.

The invention relates to a method for producing, purifying and appraising protein, in particular to a method for expression of recombinant human Abeta1-42 in Pasteur yeast as well as optimized large scale industrialized fermentation production and purification of the recombinant human Abeta1-42.

The invention provides a functional polypeptide. The functional polypeptide includes a polypeptide fragment I identifying and blocking amyloid protein A beta aggregation and a polypeptide fragment IIwhich is a mimic peptide of an apoE receptor binding region, and the polypeptide fragment I and the polypeptide fragment II are linked through a linker peptide or directly linked. The polypeptide caninhibit amyloid protein A beta aggregation, inhibit the of A beta, accelerate removal of A beta through microglia, and the functional polypeptide can be used for preparing drugs for treating the Alzheimer disease.

The invention provides a method for preparing recombinant human amyloid protein A Beta42 and application of the recombinant human amyloid protein, which belongs to the technical field of fusion protein. In the method, PCR sense primer P1 of the human amyloid A Beta42 is designed; a BamHI restriction enzyme cutting site, an anti-sense primers P2, a Sall restriction enzyme cutting site and a terminator codon TAG are introduced according to the sequence of the precusor protein APP of the human amyloid and multiple cloning sites of the cloning vector pGEX-4T-1. cDNA of human SH-SY5Y cells is taken as a templet for amplifing PCR; the length of the fragment of the product is 147bp. The Beta42 fragment of human APP from 672 to 713 is encoded. The A Beta42 gene fragment sequence is combined into a prokaryotic expression vector pGEX-4T-1 to form the prokaryotic expression plasmids pGEX-4T-1/A Beta42 of human A Beta42. PGEX-4T-1/A Beta42 is transformed into colibacillus BL21 (DE3), and purified activated recombinant human amyloid A Beta42 is got through induced expression, separation and enzyme cutting.

The invention relates to a serum amyloid protein A/procalcitonin/C-reactive protein three-in-one determination kit. The determination kit is provided with a test paper card and is characterized in that a PVC plate, a sample pad, a binding pad, a nitrocellulose membrane and a water absorbing pad are sequentially arranged on the test paper card from bottom to top, wherein the binding pad is adsorbed with three monoclonal antibody-microsphere coupling compounds, namely antiserum amyloid protein A, antiprocalcitonin, anti-C-reactive protein which are labeled by rare earth Eu<3+> fluorescent microspheres respectively, the diameter of the rare earth fluorescent microspheres is 150nm, and the rare earth fluorescent microspheres contain rare earth lanthanide element Eu<3+>, are stable in a basic state and transmit fluorescent light with the wavelength of 615nm under the action of an excitation light source at 337nm; and the monoclonal antibodies are purified mixed monoclonal antibodies which are respectively from monoclonal antibody cell strains specific to 2-6 different antigen epitopes such as serum amyloid protein A, procalcitonin and C-reactive protein. The determination kit provided by the invention has the advantages of simple and convenient operation, quick response, high sensitivity, strong specificity and the like.

The invention discloses noble metal nano particles modified by small medicine molecules as well as a preparation method and applications of the noble metal nano particles. The preparation method comprises the following steps: placing a noble metal target material into a medicine small-molecule solution, and ablating the noble metal target material by adopting pulse laser, thus preparing the noblemetal nano particles modified by the small medicine molecules, wherein the particle size of the noble metal nano particles modified by the small medicine molecules is 2-10 nm, and the modification amount of the small medicine molecules is 0.05-0.8 wt%. The noble metal nano particles can be used for preparing medicines for treating or preventing the neurodegenerative disease, namely the Alzheimer'sdisease. The preparation method provided by the invention is easy to operate, the reaction is rapid, and the prepared noble metal nano particles modified by the small medicine molecules have the effect of obviously inhibiting the aggregation of amyloid protein Abeta, and have the broad application prospect in the research and development of the medicines for treating the Alzheimer's disease.

The invention provides a detection device for simultaneously and quantitatively detecting SAA/PCT/CRP. The detection device for simultaneously, rapidly and quantitatively detecting SAA/PCT/CRP is composed of human serum amyloid A (SAA) test paper, human procalcitonin (PCT) test paper, C-reactive protein (CRP) test paper, a triplicate card case and an immunochromatography interpretation result recorder carrying a corresponding judgment method and a standard curve, wherein the human serum amyloid A (SAA) test paper, the human procalcitonin (PCT) test paper and the C-reactive protein (CRP) test paper are independent. The detection device is suitable for on-site detection, a detection method is easy, convenient and stable, the situation that a large number of blood samples are extracted is not needed, medical cost is reduced, sensitivity is high, and SAA/PCT/CRP can be simultaneously, rapidly and quantitatively detected.

The invention provides a kit for joint detection of C-reactive protein (CRP), procalcitonin (PCT) and serum amyloid A (SAA), and a preparation method of the kit. The kit comprises a CRP monoclonal antibody solution, a PCT monoclonal antibody solution and an SAA monoclonal antibody solution which are respectively labeled with magnetic particles, a carrier enveloped with a CRP monoclonal antibody, acarrier enveloped with a PCT monoclonal antibody, a carrier enveloped with an SAA monoclonal antibody, a carrier enveloped with a goat anti-mouse antibody, and a nitrocellulose membrane test strip. The preparation method comprises the following steps: respectively labeling the CRP monoclonal antibody, the PCT monoclonal antibody and the SAA monoclonal antibody with the magnetic particles; respectively enveloping the carriers with the CRP monoclonal antibody, the PCT monoclonal antibody, the SAA monoclonal antibody and the goat anti-mouse antibody; subpackaging and assembling to obtain the finished product. The kit can rapidly, quantitatively and accurately detect three markers at the same time.

The invention relates to a serum amyloid protein A and procalcitonin two-in-one determination kit and a preparation method. The kit is provided with a test paper card, and the test paper card is characterized by being provided with a PVC plate, a sample pad, a combination pad, a nitrocellulose membrane and a water absorption pad from top to bottom in order. Specifically, rare earth Eu<3+> fluorescent microsphere respectivel labelled anti-serum amyloid protein A and anti-procalcitonin two monoclonal antibody-microsphere coupled compounds are adsorbed on the combination pad, the rare earth fluorescent microsphere has a diameter of 150nm, the rare earth fluorescent microsphere contains rare earth lanthanide Eu<3+>, is stable under a ground state, and can emit fluorescence with a wavelength of 615nm under the action of a 337nm excitation light source. The monoclonal antibodies are purified mixed monoclonal antibodies, and are respectively derived from monoclonal antibody cell lines directed at 2-6 different serum amyloid proteins A and procalcitonin epitopes. The kit has the advantages of simple operation, quick response, high sensitivity and strong specificity, etc.

The invention relates to a testing reagent for serum amyloid protein A and a preparation method of the testing reagent and belongs to the technical field of testing of biochemical means. The testing reagent comprises a reagent R1, a reagent R2 and a serum amyloid protein A standard substance, wherein main ingredients of the reagent R1 are trihydroxymethyl aminomethane and NaN3; main ingredients of the reagent R2 are latex granules enveloping antibodies resisting to human serum amyloid protein A as well as NaN3; main ingredients of the serum amyloid protein A standard substance are serum amyloid protein A, bovine serum albumin, a phophate buffer solution and NaN3. The testing reagent is used for testing serum amyloid protein A and has the advantages of fastness, sensitivity, good accuracy, good stability, simplicity and convenience in operation and the like.

The invention belongs to the technical field of biotechnology and gene engineering, and particularly relates to an A[beta]42 modified protein, and an expression and purification method of the A[beta]42 modified protein in escherichia coli. An A[beta]42 expression system constructed by the method provided by the invention provides a construction method of a human amyloid protein A[beta]42 expression vector of prokaryotic expression; the expression vector is introduced into an escherichia coli expression host, and a targeted A[beta]42-His protein with high-purity biological activity is obtainedafter induced expression, two-step purification and identification. A large intestine expression system adopted by the method has the characteristics of high expression efficiency, large expression quantity, low cost, easy operation and the like. Obtained A[beta]42 polypeptide contains an His tag and is convenient to purify; the purity is high; and the yield is high. Compared with chemical synthesis of the A[beta]42, the method provided by the invention has the advantages of better aggregation characteristic, cytotoxicity and the like.

The invention relates to a kit for detecting SAA (serum amyloid A) with a spatial proximity chemiluminescence method and a detection method of the kit. The kit comprises an enzyme marker, a luminescent marker, an adjuvant, a trigger and a calibrator, wherein the calibrator contains calibration products of SAA antigens with different concentrations and a 0.1 M phosphate diluent; the enzyme marker contains components of a peroxidase labeled SAA detection antibody and a 0.05 M phosphate buffer; the luminescent marker contains components of a 9,10-dihydracridine labeled PCT capture antibody and 0.05 M Tris buffer; the adjuvant contains components of a luminescent adjuvant and a citrate buffer. A reagent spatial proximity luminescence analysis detection technology is adopted serves as a true homogeneous chemiluminescence technology, cleaning and a carrier are not needed, a coating process is omitted, and detection sensitivity and specificity are high, so that detection results are more realand reliable; meanwhile, reaction time and reaction steps are optimized, and operation is simpler.

The invention relates to a serum amyloid protein A (SAA) measuring kit, and a measuring method thereof, and belongs to the technical field of medicine biological detection. The kit comprises a reagent (1), a reagent (2), a calibration material, and a quality control material. The reagent (1) comprises Tris-HCl, sodium azide, and PEG-6000. The reagent (2) comprises Tris-HCl, emulsion particles with an embedded anti-human serum amyloid protein A antibody, sodium azide, octyl phenol polyoxyethylene, and methyl paraben. The calibration material comprises a serum amyloid protein A antigen, and sodium azide. The quality control material comprises a serum amyloid protein A antigen, and sodium azide. The provided serum amyloid protein A (SAA) measuring kit and measuring method thereof have the advantages that compared with the latex immunological turbidimetry technology, the analysis sensitivity is high, the results are accurate, the operation is simple, and the cost is proper, and thus the method is convenient for popularization.

The invention belongs to the field of life science research, and in particular relates to applications of an antagonist of serotonin receptor subtype 6 in preparing amyloid protein beta-amyloid inhibitors. According to the applications, for the first time, the elisa experiment is adopted for proving that an activating agent and the antagonist targeting to the serotonin receptor subtype 6 can reduce the generation of the amyloid protein beta-amyloid on the human nerve cell line, in the cerebrospinal fluid of patients, the concentration change of beta-amyloid is earlier than the change of the tau protein level, the deposition of amyloid protein is also earlier than the occurrence of the clinical symptoms, and considering that the process from the accumulation of beta-amyloid small peptide tothe plaque formation depends on the concentration of beta-amyloid, the searching for the method for reducing the concentration of beta-amyloid is very important for treatment. Therefore, the disclosure for the fact that the activating agent and the antagonist targeting to the serotonin receptor subtype 6 can reduce the generation of beta-amyloid and for the related mechanism can provide the guiding significance of the clinical experiment for the treatment of the alzheimer disease and the further research and development of medicines.

The invention provides a method for quantitatively detecting SAA/PCT/CRP (Serum Amyloid Protein A/Procalcitonin/C-Reactive Protein) simultaneously. Test paper of human SAA, test paper of PCT and test paper of CRP, which are mutually independent, a triple card shell and an immunochromatographic interpretation result recorder with a corresponding judgment method and a standard curve are used for quantitatively detecting SAA/PCT/CRP simultaneously and rapidly. The detection method is simple and stable and does not require a large number of samples, thereby reducing the medical cost; and the method has high sensitivity and can rapidly and quantitatively detect SAA/PCT/CRP simultaneously.

The invention provides a manufacturing method of a detection device for quantitatively detecting SAA/PCT/CRP at the same time. Through independently placing serum amyloid A (SAA), procalcitonin (PCT) and C-reactive protein (CRP) detection test paper, a triple clamping shell and an immunochromatography interpretation result recorder with a corresponding determining method and a standard curve are utilized for forming the detection device for rapidly and quantitatively detecting the SAA/PCT/CRP at the same time. By the utilization of the detection device, operation is easy and convenient, the result is stable, a lot of blood samples do not need to be drawn, and accordingly medical costs are reduced, sensitivity is high, and the SAA/PCT/CRP can be rapidly and quantitatively detected at the same time.

The present invention relates to the discovery that acute-phase serum amyloid protein A (A-SAA) is a biomarker for obesity and certain abnormal conditions. The present invention, therefore, provides methods of diagnosing obesity or an abnormal condition in a subject The present invention also provides methods of monitoring the progression of obesity or an abnormal condition in a subject. The present invention also relates to treating obesity or an abnormal condition comprising reducing the levels of active SAA1 and/or SAA2 in a subject in need thereof.